Fresenius

Updated:

April 19, 2024

Medical

Tenant Description

Fresenius Medical Care, established in 1996 through a merger of Fresenius Worldwide Dialysis and the National Medical Care Company, has ascended to become a global leader in dialysis services and products. The company operates a vast network of over 3,900 dialysis clinics across more than 150 countries, serving over 345,000 patients worldwide. This expansive reach underscores Fresenius' commitment to addressing the critical needs of individuals with chronic kidney disease and end-stage renal disease.

Fresenius Medical Care offers a comprehensive suite of dialysis services, including hemodialysis, peritoneal dialysis, and home dialysis, along with manufacturing a wide range of dialysis products such as dialysis machines, dialyzers, and related disposables. The company's integrated approach to care, combining treatment services with product innovation, allows for a highly personalized patient experience, enhancing both the effectiveness of treatments and patient quality of life.

Innovation is at the core of Fresenius' mission, with significant investments in research and development to advance dialysis technology and improve clinical outcomes. The company's focus on innovation extends to digital health solutions, aiming to enhance patient care through telemedicine, remote monitoring, and data analytics. These technological advancements support Fresenius' goal of making dialysis more accessible, efficient, and patient-friendly.

Fresenius' strategic expansion has been characterized by both organic growth and strategic acquisitions, enabling the company to enter new markets and expand its service offerings. The choice of clinic locations is strategic, ensuring they are accessible to patients, often situated in areas with high demand for renal care services.

Financially, Fresenius Medical Care has shown strong performance, with a solid track record of revenue growth and profitability. This financial stability, coupled with a comprehensive care model and a global presence, positions Fresenius as an attractive and reliable tenant in the healthcare real estate sector. The company's commitment to advancing kidney care and improving patient outcomes makes it a valuable addition to any community, contributing not only to local healthcare infrastructure but also to the overall well-being of its residents.

Average Asking Cap Rate

6.17%

3 mo avg (260 properties)

Typical Investment/Lease

Average Sale Price

$3,973,884

Rent

$221,278

$/Square Foot

$390 - $500

Building SF

10,000 - 18,500

Approx. Store Count

2,277

Lease Term

10 Years

Escalations

10% Every 5 Years

Stock Symbol

FSNUY

Credit Quality

S&P:

BBB

Average Asking Cap Rate Trend

5.24%

2022

5.66%

2023

Reflect only properties with long-term lease.

Need Capital for an STNL Development?

We offer a full capital stack solution for BTS and ground lease developments.

Menu